Cellectar BioSciences Presents Phase 3 Trial Plan for Iopofosine in Waldenström Macroglobulinemia

Bitget2026/10/29 19:42

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cellectar BioSciences plans to submit an FDA accelerated approval application for iopofosine I 131 in Waldenström macroglobulinemia in the first half of 2027.
Potential US accelerated approval is targeted for the second half of 2027.
The Phase 3 confirmatory trial targets approximately 200 patients, with first enrollment projected for the first quarter of 2027.
Phase 2b data showed an 83.6% overall response rate; median response duration reached 17.8 months.
Estimated total Phase 3 trial cost is $42 million, with progression-free survival data expected 24–30 months following first patient enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cellectar BioSciences Presents Phase 3 Trial Plan for Iopofosine in Waldenström Macroglobulinemia

You may also like

Crypto prices